Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- More Manpower, Knowledge Necessary for Giving New Drugs World’s First Approval: PMDA Chief Executive
January 17, 2014
- Chuikyo Approves General Proposal on Next Medical Fee Revision, Postpones Decision on Divided Dispensing
January 17, 2014
- Varicella, Adult Pneumococcal Vaccines to Join Japan’s Routine Immunization Program in October
January 16, 2014
- PMDA Posts RMPs for Rheumatoid Arthritis Treatment Iguratimod
January 16, 2014
- PFSB Calls for Revision of Package Inserts for Diabetes Drugs Including Lyxumia
January 15, 2014
- PAFSC’s First Committee to Review Second SGLT-2 Inhibitor Dapagliflozin on Jan 24
January 15, 2014
- MHLW Begins Probe into Suspected Data-Tampering of J-ADNI Project
January 15, 2014
- MHLW to Decide Measures by March 2014 to Improve Price Settlement Rates: Ministry Official
January 14, 2014
- Diovan Scandal Could Undermine Confidence in Clinical Studies: Minister Tamura
January 14, 2014
- MHLW Proposes that Medical Institutions Clarify in Invoices that Consumption Tax Is Included in Drug Prices
January 14, 2014
- Did Novartis Employees “Willfully” Use Rigged Data in Diovan Ads? Statute of Limitations Will Pose Hurdles to Chase Key Figure
January 10, 2014
- MHLW Seeks Criminal Charges against Novartis over Suspected PAL Violations, Diovan Ads Allegedly Misleading
January 10, 2014
- MHLW Files Criminal Complaint against Novartis over Diovan Ads
January 9, 2014
- Guidance on Companion Diagnostics Calls for Inclusion of Biomarker-Negative Subjects in Clinical Studies
January 8, 2014
- MHLW Adds Precaution for Driving in Package Inserts of Donepezil and Other Drugs
January 8, 2014
- MHLW to File Criminal Complaint against Novartis Jan. 8
January 8, 2014
- MHLW Economic Affairs Official Says Shakeout in Generic Sphere “Inevitable”
January 7, 2014
- HSB Invites Additional Applicants for New Flu Vaccine Development and Production Project
January 7, 2014
- Discarded Plan to Institutionalize Key Premium Still Faces Backlash; Rough Sailing Expected before Next Reform
December 27, 2013
- Shiga University of Medical Science Wants to Correct Diovan Paper, Sent Data Found During Diovan Probe to US Journal
December 27, 2013
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…